CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 205 enrolled
Drug / intervention
LY3561774 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05256654
NCT05256654Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia

Eli Lilly and Company·interventional·Posted Feb 25, 2022·Updated Mar 17, 2025

In Brief

A Phase 2 clinical trial evaluating LY3561774 and Placebo for Dyslipidemias and 3 related conditions. Completed, enrolled 205 participants across 41 sites in 7 countries.

Detailed Summary

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
CountriesArgentina, Canada, Japan, Mexico, Poland, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedFeb 25, 2022
Enrollment StartJul 20, 2022
Primary CompletionMar 4, 2024
Study CompletionMay 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.4 years ago

Interventions

LY3561774drug

Administered SC

Placebodrug

Administered SC